Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields


Manjari Pandey 1, Joanne Xiu 2, Sandeep Mittal 3, Jia Zeng 2, Michelle Saul 2, Santosh Kesari 4, Amir Azadi 5, Herbert Newton 6, Karina Deniz 7, Katherine Ladner 7, Ashley Sumrall 8, W Michael Korn 1, Emil Lou 7


The genomic and overall biologic landscape of glioblastoma (GB) has become clearer over the past 2 decades, as predictive and prognostic biomarkers of both de novo and transformed forms of GB have been identified. The oral chemotherapeutic agent temozolomide (TMZ) has been integral to standard-of-care treatment for nearly 2 decades. More recently, the use of non-pharmacologic interventions, such as application of alternating electric fields, called Tumor-Treating Fields (TTFields), has emerged as a complementary treatment option that increases overall survival (OS) in patients with newly diagnosed GB. The genomic factors associated with improved or lack of response to TTFields are unknown.

External Link